SCHEMBL5565370

SCHEMBL5565370

C=C(C(=O)c1ccc(S(=O)(=O)Nc2nccs2)cc1)c1cc(-c2cccs2)c(OC)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 2/20 0.51
PKM P14618 2/20 0.51
SCN9A Q15858 12/20 0.48
MAPK1 P28482 2/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
ALOX12 P18054 1/20 0.47
POLB P06746 1/20 0.46
CNR1 P21554 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5566988 0.90 KMT2A (0.51) MEN1KMT2AALDH1A1MAPK1LMNA
SCHEMBL5560946 0.89 RXFP1 (0.49) MEN1KMT2AALDH1A1MAPK1ALOX12
SCHEMBL5565512 0.85 SLC22A12 (0.42) KMT2ASCN9A
SCHEMBL5565133 0.85 HTT (0.46) MEN1KMT2AALDH1A1SCN9ALMNA
SCHEMBL5565448 0.85 CA2 (0.36) MEN1KMT2AALDH1A1MAPK1ALOX12
SCHEMBL5564202 0.84 HPGD (0.49) MEN1KMT2AALDH1A1MAPK1GAA
SCHEMBL5565466 0.84 SCN9A (0.41) SCN9A
SCHEMBL5560084 0.83 HPGD (0.49) MEN1KMT2AALDH1A1MAPK1GAA
SCHEMBL5560048 0.83 TNFRSF1A (0.42) SCN9A
SCHEMBL6879563 0.82 TNFRSF1A (0.41) MEN1KMT2AALDH1A1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 MEN1 2929/4885KMT2A 3609/4885ALDH1A1 1653/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 MEN1 2929/4885KMT2A 3609/4885ALDH1A1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.